Enzolytics Inc (ENZC)

[DOGONE]

NEWS-->

Enzolytics Inc. and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-HIV and Anti-SARS-CoV-2
October 7, 2021, 8:00 AM EDT
SHARE THIS ARTICLE
Share
Tweet
Post
Email

Enzolytics Inc. and Samsung Biologics Announce Development and Manufacturing
Agreement for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies

PR Newswire

COLLEGE STATION, Texas and INCHEON, South Korea, Oct. 7, 2021

o Enzolytics Inc. to leverage Samsung Biologics' development and
manufacturing expertise to advance both Anti-HIV and Anti-SARS-CoV-2
Monoclonal Antibody Therapies to IND.
o Samsung Biologics to offer a seamless, end-to-end CDMO service with
support from its San Francisco R&D Center.

COLLEGE STATION, Texas and INCHEON, South Korea, Oct. 7, 2021 /PRNewswire/
-- Samsung Biologics (KRX: 207940. K.S.), a leading contract development and
manufacturing organization and Enzolytics (ENZC), a drug development company
committed to commercializing multiple proprietary therapeutics to treat
debilitating infectious diseases, announced the signing of a strategic CDMO
partnership agreement.

Enzolytics Inc. and Samsung Biologics Announce Development and Manufacturing
Agreement for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies

Under the terms of the agreement, Samsung Biologics will provide end-to-end
CDMO services from cell line development, clinical drug substance, and drug
product manufacturing services to support IND filings for Anti-HIV and
Anti-SARS-CoV-2 Monoclonal Antibodies for the treatment of HIV and SARS-CoV-2.
In addition, there will be continuing discussions for other Monoclonal
Antibodies being developed by Enzolytics.

The Enzolytics protocol offers the opportunity to implement A.I. analysis and
provides a platform for creating multiple fully human Monoclonal Antibodies
targeting conserved immutable sites on the virus and offering a cure for these
viruses. A stable cell line will be manufactured with support from Samsung
Biologics' R&D Center in San Francisco. Its related clinical trial materials
will be manufactured at Samsung Biologics headquarters in Incheon, South
Korea.

"Partnering with Enzolytics reinforces the value of our fully integrated,
end-to-end business model, which is designed to meet the unique needs and
goals of our biotech clients," said John Rim, CEO of Samsung Biologics. "We
look forward to providing comprehensive services and professional support for
the manufacturing of this important class of Monoclonal Antibody therapeutics
for the treatment of HIV and SARS-CoV-2, helping to accelerate the process of
drug development to IND filing and bring these life-saving products to
patients."

"The collaboration with Samsung Biologics is a significant milestone for
Enzolytics' Artificial Intelligence enabled Monoclonal Antibody Platform. We
chose to partner with Samsung Biologics because of Samsung Biologics'
extensive experience and expertise in developing, producing, and manufacturing
Monoclonal Antibodies for Infectious Diseases and Oncology." said Dr. Gaurav
Chandra, Chief Operating Officer Research and Development at Enzolytics. "This
partnership marks a pivotal milestone for Enzolytics to significantly advance
the clinical development of our universal, durable, broadly neutralizing
Monoclonal Antibodies and reduce time to the clinic and offer the much-needed
treatment for patients."

About Enzolytics Inc.

Enzolytics Inc. is a drug development company committed to commercializing its
multiple proprietary therapeutics to treat debilitating infectious diseases.
The Company's patented ITV-1 therapeutic suspension of Inactivated Pepsin
Fraction (IPF), which studies have shown effectively treats HIV/AIDS. IPF is
the active component of ITV-1 and is a purified extract of porcine pepsin.
ITV-1 has also been shown to modulate the immune system. Additionally, the
Company has proprietary technology for producing fully human monoclonal
antibodies (mAbs) against infectious diseases, including HIV, Coronavirus,
HTLV-1, Influenza A, and B, H10N3, H1N1 influenza, Respiratory syncytial virus
(RSV), Ebola, Small-Pox, Herpes zoster, Varicella zoster, Elephant
endotheliotropic herpesviruses, Feline Leukemia Virus, Equine Infectious
Anemia Virus, and Koala retrovirus.

Enzolytics Safe Harbor Statement

This news release contains forward-looking statements that involve risks and
uncertainties associated with financial projections, budgets, milestone
timelines, clinical development, regulatory approvals, and other risks
described by Enzolytics, Inc. from time to time in its periodic reports filed
with the SEC. ITV-1 is not approved by the U.S. Food and Drug Administration
or by any comparable regulatory agencies elsewhere in the world.

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering
state-of-the-art contract development, manufacturing, and laboratory testing
services. With proven regulatory approvals, the largest capacity, and the
fastest throughput, Samsung Biologics is an award-winning partner of choice
and is uniquely able to support the development and manufacturing of biologics
products at every stage of the process while meeting the evolving needs of
biopharmaceutical companies worldwide. For more information, visit
www.samsungbiologics.com

Samsung Biologics Forward-Looking Statement

This press release contains certain statements that constitute forward-looking
statements, including statements that describe Samsung Biologics' objectives,
plans or goals. All such forward-looking statements, and the assumptions on
which they are based, are subject to certain risks and uncertainties that
could cause actual results to differ materially from those contemplated by the
relevant forward-looking statements. There can be no assurance that the
results and events contemplated by the forward-looking statements contained
herein will in fact occur. Except as required by law, Samsung Biologics will
not update any forward-looking statements to reflect material developments
that may occur after the date of this press release.

Enzolytics Investor Relations Contact:

Ten Associates, LLC

NEWS----->
NEWS-->





Tom Nelson
Enzolytics, Inc.
2000 North Central Expressway
Plano, TX 75074 USA

Samsung Biologics Contact:

Senior Director of Global Public Relations
Claire Kim
[e-mail]

Cision View original content to download
multimedia:https://www.prnewswire.com/news-releases/enzolytics-inc-and-samsung-biologics-announce-development-and-manufacturing-agreement-for-anti-hiv-and-anti-sars-cov-2-monoclonal-antibody-therapies-301394969.html

SOURCE Samsung Biologics

Website: https://samsungbiologics.com/en